Anahat Kaur

ORCID: 0000-0003-0559-4584
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chronic Lymphocytic Leukemia Research
  • Global Cancer Incidence and Screening
  • COVID-19 and healthcare impacts
  • Lymphoma Diagnosis and Treatment
  • Neuroendocrine Tumor Research Advances
  • Lung Cancer Treatments and Mutations
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Palliative Care and End-of-Life Issues
  • Blood disorders and treatments
  • Venous Thromboembolism Diagnosis and Management
  • Multiple and Secondary Primary Cancers
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Colorectal Cancer Screening and Detection
  • Immunodeficiency and Autoimmune Disorders
  • Blood Coagulation and Thrombosis Mechanisms
  • Hemophilia Treatment and Research
  • Cancer survivorship and care
  • Lung Cancer Research Studies
  • Abdominal vascular conditions and treatments
  • Parathyroid Disorders and Treatments
  • DNA Repair Mechanisms
  • Telemedicine and Telehealth Implementation
  • Intraperitoneal and Appendiceal Malignancies
  • Vascular Malformations and Hemangiomas
  • CNS Lymphoma Diagnosis and Treatment

Albert Einstein College of Medicine
2020-2024

Jacobi Medical Center
2021-2024

University of Missouri–Kansas City
2018-2022

University of Kentucky
2022

University of Nebraska Medical Center
2019-2022

Tulane University
2022

Sanford USD Medical Center
2022

Saint Luke's Hospital
2019-2022

University of Cincinnati
2019

St. Luke's Hospital
2019

Background: : Incidence of hepatocellular cancer (HCC) in the Bronx is 61% higher than rest New York State. Underserved populations are not well represented clinical trials immune checkpoint inhibitors (ICI). Methods: Demographics were tabulated for 194 patients treated with ICI at Montefiore-Einstein Comprehensive Cancer Center (MECCC) between 2017 and 2022. Categorical variables analyzed by Chi-squared test, survival was using Kaplan–Meier (KM) curves. Results: MECCC 40.7% Hispanic 20.6%...

10.2147/jhc.s436804 article EN cc-by-nc Journal of Hepatocellular Carcinoma 2024-02-01

Anemia is a common finding in alcoholics. It often multifactorial and caused by combination of liver dysfunction, ineffective erythropoiesis, poor nutrition. Zieve's syndrome (ZS) clinical that presents with triad jaundice, hemolytic anemia, hyperlipidemia secondary to alcohol use. Herein, we present case 58-year-old male history cirrhosis who presented after fall due binge drinking was found have severe anemia. Workup consistent anemia no source active bleeding. The patient managed...

10.7759/cureus.4121 article EN Cureus 2019-02-22

Primary pancreatic lymphoma is a rare form of cancer that represents diagnostic and therapeutic challenge due to its rarity presentation mimicking adenocarcinoma. Herein, we report case 57-year-old Caucasian male who presented with left-sided chest pain, epigastric melena. Abdominal imaging was remarkable for large, necrotic mass near the tail pancreas extending into splenic hilum left kidney. Biopsy confirmed B-cell origin. The patient diagnosed Stage IV disease started on chemotherapy....

10.7759/cureus.5479 article EN Cureus 2019-08-25

Sweet's syndrome is an acute febrile neutrophilic dermatosis which can be associated with anticancer drugs. Herein we report two cases of in association recently approved drugs for myeloid leukemia: FLT3 inhibitor Midostaurin and IDH 2 Enasidenib. In both cases, there was temporal between initiation drug development characteristic clinical features biopsy findings consistent syndrome. Improvement symptoms steroids eventual resolution prednisone taper further strengthened suspicion drug-induced

10.1002/acg2.61 article EN Advances in Cell and Gene Therapy 2019-04-29

Hyperinflammatory syndrome with breakthrough coronavirus disease 2019 (COVID-19) infection in a fully vaccinated patient is not common finding. To the best of our knowledge, this first such case who received Spikevax/Moderna (elasomeran mRNA-1273) vaccine. The exhibited clinical characteristics consistent both multisystem inflammatory adults (MIS-A) and hemophagocytic lymphohistiocytosis (HLH), thus posing diagnostic challenge. Multi-inflammatory COVID-19 patients frequently seen pediatric...

10.7759/cureus.22123 article EN Cureus 2022-02-11

Abstract The incidence of hepatocellular cancer (HCC) in the Bronx is 61% higher than rest New York State. Underserved populations are not well represented clinical trials immune checkpoint inhibitors. purpose this study to analyze efficacy immunotherapy treatment a diverse and underserved patient population Bronx. Study demographics include 194 patients treated with ICI at Montefiore Einstein Comprehensive Cancer Center (MECCC) between 2017 2022. A retrospective electronic medical record...

10.1158/1538-7445.am2024-3722 article EN Cancer Research 2024-03-22

Werner syndrome (WS) is rare adult-onset progeria characterized by premature aging and early death. Patients develop normally until adolescence usually present in adulthood. Our case highlights a common presentation of this uncommon disease, wherein 29-year-old non-obese male with no known risk factors developed uncontrolled diabetes, hypertriglyceridemia, rapidly progressive atherosclerotic vascular disease. Careful observation attention to the presence characteristic physical features...

10.7759/cureus.4743 article EN Cureus 2019-05-24

Anabolic-androgenic steroids (AASs) are commonly implicated in thromboembolic events but rarely cause diffuse alveolar haemorrhage. We report the case of a Caucasian man his late 40s who was consuming supratherapeutic doses AAS and presented with shortness breath haemoptysis. Chest imaging showed bilateral patchy infiltrates lungs blood throughout airways on bronchoscopy. Extensive infectious autoimmune workup were unremarkable. The patient then developed right foot ischaemia found to have...

10.1136/bcr-2023-254817 article EN BMJ Case Reports 2023-08-01

e18790 Background: Anosmia is a rare and under-reported adverse event associated with the use of several oncologic drugs. Instances olfactory disturbances following administration chemotherapeutic agents have been sporadically documented in case reports series. We aimed to conduct more comprehensive study generate signal for anosmia as effect drugs used indications. Methods: The United States Food Drug Administration (FDA) Adverse Events Reporting System (FAERS) database, pharmacovigilance...

10.1200/jco.2021.39.15_suppl.e18790 article EN Journal of Clinical Oncology 2021-05-20

Objectives Functional neuroendocrine tumors (FNETs) are characterized by excess secretion of disease-specific hormones. In this study, we attempted to define survival trends in patients with some these uncommon tumors. Methods Using the Surveillance, Epidemiology, and End Results database, 529 FNETs (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma) were identified. We analyzed patient tumor characteristics, overall survival, cancer-specific survival. found be more predominant...

10.1097/mpa.0000000000002171 article EN Pancreas 2022-10-01

Diffuse large B-cell lymphoma (DLBL) is an aggressive type of non-Hodgkin (NHL). Renal involvement in NHL not uncommon advanced stages; however, it rare to have kidneys affected early the course disease. Usual chemotherapy regimen for DLBL rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (R-CHOP). This a case 50-year-old female diagnosed with who presented bilateral renal at disease onset also underwent complete remission after six cycles dose-adjusted etoposide,...

10.7759/cureus.3814 article EN Cureus 2019-01-02

e19034 Background: Multiple studies have attempted to identify parameters predict prognosis and overall survival (OS) in Non-Hodgkin Lymphoma (NHL). Revised International Prognostic Index (R-IPI) is commonly used but does not capture all predictive risk factors the Rituximab era. Low absolute lymphocyte count (ALC) on follow up after first line therapy has been reported relapse. The prognostic value exact cut off for low ALC at diagnosis known. We aimed investigate whether time of an...

10.1200/jco.2019.37.15_suppl.e19034 article EN Journal of Clinical Oncology 2019-05-20
Coming Soon ...